source
- Aspen Neuroscience and Bambusa raise $310M combined in IPOsAspen Neuroscience, a biotech focused on cell therapy for Parkinson's disease, announced it will raise about $141 million through its initial public offering scheduled for Friday. Bambusa, a start…
- Sanofi eyes 'moonshot' drug acquisitions to offset upcoming Dupixent patent lossSanofi's CFO Francois-Xavier Roger told Fierce that the company is looking at 'moonshot' treatments as potential acquisition targets to rebuild its pipeline. The push comes as the U.S. patent on D…